Medtronic Plc (NYSE:MDT) reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion. The ...

Medtronic PLC (MDT) reports robust revenue and EPS growth, driven by innovations in Cardiac Ablation and Leadless Pacing, ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

Medtronic (MDT) stock slips as the company reaffirms full-year outlook after delivering mixed financial for Q3 fiscal 2025.

Q3 2025 Earnings Call Transcript February 18, 2025 Medtronic plc beats earnings expectations. Reported EPS is $1.39, ...

Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

Reports Q3 revenue $8.29B, consensus $8.33B. “We delivered strong earnings this quarter, with significant improvements in both our gross margin ...

Medtronic MDT came up with a mixed performance for the third quarter of fiscal 2025, sparking investor concerns and a ...

Medtronic stock was down stock was down today after its third-quarter revenue slightly missed the Wall Street analyst consensus.

Medtronic's Q3 adjusted EPS of $1.39 surpassed forecasts by $0.03. Revenue of $8.29 billion fell short of expectations by $40 million. Premarket trading saw a 4.48% drop in Medtronic's stock price.

The medical device company posted revenue of $8.29 billion in the period, falling short of Street forecasts. Ten analysts surveyed by Zacks expected $8.33 billion. Medtronic expects full-year earnings ...